{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:35:37Z","timestamp":1777401337620,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03465-x","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:14:13Z","timestamp":1741742053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interferon alpha-2b versus 5-fluorouracil as primary treatment modalities for ocular surface squamous neoplasia: a study of 116 eyes"],"prefix":"10.1007","volume":"45","author":[{"given":"Komal","family":"Bakal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-9961","authenticated-orcid":false,"given":"Swathi","family":"Kaliki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"11","key":"3465_CR1","first-page":"NC10","volume":"9","author":"PP Dandala","year":"2015","unstructured":"Dandala PP, Malladi P, Kavitha (2015) Ocular surface squamous neoplasia (OSSN): a retrospective study. J Clin Diagn Res 9(11):NC10\u2013NC13","journal-title":"J Clin Diagn Res"},{"key":"3465_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","volume":"115","author":"JA Shields","year":"1997","unstructured":"Shields JA, Shields CL, De Potter P (1997) Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan lecture. Arch Ophthalmol 115:808\u2013815","journal-title":"Arch Ophthalmol"},{"key":"3465_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40662-019-0150-5","volume":"6","author":"G Al Bayyat","year":"2019","unstructured":"Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N, Galor A, Karp CL (2019) Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis 6:24","journal-title":"Eye Vis"},{"key":"3465_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/ICU.0b013e3283622a13","volume":"24","author":"AA Nanji","year":"2013","unstructured":"Nanji AA, Sayyad FE, Karp CL (2013) Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol 24:336\u2013342","journal-title":"Curr Opin Ophthalmol"},{"key":"3465_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","volume":"121","author":"AA Nanji","year":"2014","unstructured":"Nanji AA, Moon CS, Galor A, Sein J, Oellers P, Karp CL (2014) Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology 121:994\u20131000","journal-title":"Ophthalmology"},{"key":"3465_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17469899.2017.1263567","volume":"12","author":"IO Sayed-Ahmed","year":"2017","unstructured":"Sayed-Ahmed IO, Palioura S, Galor A, Karp CL (2017) Diagnosis and medical management of ocular surface squamous neoplasia. Expert Rev Ophthalmol 12:11\u201319","journal-title":"Expert Rev Ophthalmol"},{"key":"3465_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41433-023-02434-x","volume":"37","author":"D Monroy","year":"2023","unstructured":"Monroy D, Serrano A, Galor A, Karp CL (2023) Medical treatment for ocular surface squamous neoplasia. Eye (Lond) 37:885\u2013893","journal-title":"Eye (Lond)"},{"key":"3465_CR8","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/S0161-6420(97)30055-4","volume":"104","author":"J Frucht-Pery","year":"1997","unstructured":"Frucht-Pery J, Sugar J, Baum J et al (1997) Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology 104:2085\u20132093","journal-title":"Ophthalmology"},{"key":"3465_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/IOP.0b013e3181ac4c39","volume":"25","author":"PL Ballalai","year":"2009","unstructured":"Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN (2009) Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthalmic Plast Reconstr Surg 25:296\u2013299","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3465_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0002-9394(14)73072-7","volume":"117","author":"J Frucht-Pery","year":"1994","unstructured":"Frucht-Pery J, Rozenman Y (1994) Mitomycin C therapy for corneal intraepithelial neoplasia. Am J Ophthalmol 117:164\u2013168","journal-title":"Am J Ophthalmol"},{"key":"3465_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/bjo.2005.086850","volume":"90","author":"JJ Khong","year":"2006","unstructured":"Khong JJ, Muecke J (2006) Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 90:819\u2013822","journal-title":"Br J Ophthalmol"},{"key":"3465_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","volume":"36","author":"R Kusumesh","year":"2017","unstructured":"Kusumesh R, Ambastha A, Kumar S, Sinha BP, Imam N (2017) Retrospective comparative study of topical interferon \u03b12b versus mitomycin C for primary ocular surface squamous neoplasia. Cornea 36:327\u2013331","journal-title":"Cornea"},{"key":"3465_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1442-6404.2002.00497.x","volume":"30","author":"M Daniell","year":"2002","unstructured":"Daniell M, Maini R, Tole D (2002) Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol 30:94\u201398","journal-title":"Clin Exp Ophthalmol"},{"key":"3465_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ceo.12377","volume":"43","author":"AK Rudkin","year":"2015","unstructured":"Rudkin AK, Dempster L, Muecke JS (2015) Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy. Clin Exp Ophthalmol 43:20\u201325","journal-title":"Clin Exp Ophthalmol"},{"key":"3465_CR15","first-page":"20","volume":"2","author":"JE Houglum","year":"1983","unstructured":"Houglum JE (1983) Interferon: mechanisms of action and clinical value. Clin Pharm 2:20\u201328","journal-title":"Clin Pharm"},{"key":"3465_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/bjo.2008.153197","volume":"94","author":"A Galor","year":"2010","unstructured":"Galor A, Karp CL, Chhabra S, Barnes S, Alfonso EC (2010) Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol 94:551\u2013554","journal-title":"Br J Ophthalmol"},{"key":"3465_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4103\/ijo.IJO_1665_20","volume":"69","author":"CL Shields","year":"2021","unstructured":"Shields CL, Constantinescu AB, Paulose SA et al (2021) Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: comparative analysis of outcomes based on original tumor configuration. Indian J Ophthalmol 69:563\u2013567","journal-title":"Indian J Ophthalmol"},{"key":"3465_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4103\/0301-4738.195010","volume":"64","author":"S Kaliki","year":"2016","unstructured":"Kaliki S, Singh S, Iram S, Tripuraneni D (2016) Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients. Indian J Ophthalmol 64:702\u2013709","journal-title":"Indian J Ophthalmol"},{"key":"3465_CR19","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","volume":"123","author":"MG Joag","year":"2016","unstructured":"Joag MG, Sise A, Murillo JC et al (2016) Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology 123:1442\u20131448","journal-title":"Ophthalmology"},{"key":"3465_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5935\/0004-2749.20170032","volume":"80","author":"GA Viani","year":"2017","unstructured":"Viani GA, Fendi LI (2017) Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review. Arq Bras Oftalmol 80:131\u2013136","journal-title":"Arq Bras Oftalmol"},{"key":"3465_CR21","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.2147\/OPTH.S70459","volume":"8","author":"RJ Nutt","year":"2014","unstructured":"Nutt RJ, Clements JL, Dean WH (2014) Ocular surface squamous neoplasia in HIV-positive and HIV-negative patients and response to 5-fluorouracil in Angola. Clin Ophthalmol 8:2435\u20132440","journal-title":"Clin Ophthalmol"},{"key":"3465_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1136\/bjo.84.3.268","volume":"84","author":"E Midena","year":"2000","unstructured":"Midena E, Angeli CD, Valenti M, de Belvis V, Boccato P (2000) Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 84:268\u2013272","journal-title":"Br J Ophthalmol"},{"key":"3465_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bjo.2010.183244","volume":"95","author":"R Parrozzani","year":"2011","unstructured":"Parrozzani R, Lazzarini D, Alemany-Rubio E et al (2011) Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. Br J Ophthalmol 95:355\u2013359","journal-title":"Br J Ophthalmol"},{"key":"3465_CR24","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1038\/s41433-023-02565-1","volume":"37","author":"R H\u04e7llhumer","year":"2023","unstructured":"H\u04e7llhumer R, Michelow P, Williams S (2023) Demographics, clinical presentation and risk factors of ocular surface squamous neoplasia at a tertiary hospital. South Africa Eye (Lond) 37:3602\u20133608","journal-title":"South Africa Eye (Lond)"},{"key":"3465_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","volume":"199","author":"N Venkateswaran","year":"2019","unstructured":"Venkateswaran N, Mercado C, Galor A, Karp CL (2019) Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia. Am J Ophthalmol 199:216\u2013222","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3465_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10792-024-03105-w","volume":"44","author":"JJ San Rom\u00e1n Llorens","year":"2024","unstructured":"San Rom\u00e1n Llorens JJ, Fern\u00e1ndez-Gurria M, Artaechevarria Artieda J, Alejandre Alba N, Garc\u00eda Sandoval B, Jim\u00e9nez-Alfaro MI (2024) Efficacy, safety and cost-effectiveness of 5-fluorouracil versus interferon \u03b1-2b as adjuvant therapy after surgery in ocular surface squamous neoplasia in a southern European tertiary hospital. Int Ophthalmol 44(1):184","journal-title":"Int Ophthalmol"},{"key":"3465_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtos.2022.12.002","volume":"27","author":"A Wylegala","year":"2023","unstructured":"Wylegala A, Sripawadkul W, Zein M, Alvarez OP, Al Bayyat G, Galor A, Karp CL (2023) Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: long-term follow-up study. Ocul Surf 27:67\u201374","journal-title":"Ocul Surf"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03465-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03465-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03465-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:53Z","timestamp":1766167493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03465-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03465-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      and\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of LV Prasad Eye Institute.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"87"}}